Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
- Amylyx delisted Relyvrio due to poor Phase 3 trial results in April 2024. - Developing AMX0035 for Wolfram syndrome, PSP, and AMX0114 for ALS. - Expect data from AMX0035 Wolfram syndrome study in fall 2024. - Financials: $373.3 million in cash as of March 31, 2024. - Risks: Uncertainty in outcomes for drug developments and acquisitions. Price Impact Rating: Bearish Impact Horizon Rating: Long-term Type: Industry News
- Amylyx delisted Relyvrio due to poor Phase 3 trial results in April 2024.
- Developing AMX0035 for Wolfram syndrome, PSP, and AMX0114 for ALS.
- Expect data from AMX0035 Wolfram syndrome study in fall 2024.
- Financials: $373.3 million in cash as of March 31, 2024.
- Risks: Uncertainty in outcomes for drug developments and acquisitions.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.